M onday, H.C. Wainwright analysts increased their price target on Protalix BioTherapeutics (NYSE:PLX) stock to $15.00 from the previous $10.00 while continuing to recommend a Buy rating for the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Explore Protalix BioTherapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PLX. The Dow Jones closed lower by around 300 points on Friday.

Protalix BioTherapeutics stock opened at $2.52 on Tuesday. The stock has a market capitalization of $185.56 million, a price-to-earnings ratio of -19.38 and a beta of 0.75. Protalix ...

Y Intercept Hong Kong Ltd acquired a new position in Protalix BioTherapeutics, Inc. (NYSE:PLX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC.

Protalix Biotherapeutics, Inc. (NYSE:PLX) finds itself in an enviable position as we begin 2025. The company has two approved products generating revenues and a pipeline with multiple candidates ...

Short interest in Protalix BioTherapeutics Inc (AMEX:PLX) increased during the last reporting period, rising from 3.99M to 4.30M. This put 6.1% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...